Fact Meets Function

Ac-SDKP is rapidly broken down in the body by angiotensin-converting enzyme, giving it a very short half-life, and this study addresses that constraint directly. Researchers built an analog with two D-amino acid substitutions and measured stability against ACE and half-life in both rat and human serum by HPLC. The modified peptide resisted ACE-mediated degradation and lasted substantially longer than native Ac-SDKP. The practical point is that the limiting factor for this tetrapeptide is enzymatic clearance rather than failure to be taken up. This is laboratory and animal evidence and does not establish efficacy or safety in human populations.

This study describes Ac-SDKP, the N-terminal tetrapeptide of thymosin beta-4 and a substrate of angiotensin-converting enzyme, as an orally available peptide. Ac-SDKP was given by mouth to two mouse models of diabetic kidney disease, alone and alongside an ACE inhibitor, and oral dosing raised measured urine Ac-SDKP levels, with the combination producing the highest levels. Measured fibrosis endpoints in kidney tissue were reduced in the orally dosed groups. The rise in urine levels after oral dosing is direct evidence the peptide was absorbed. This is animal model evidence and does not establish efficacy or safety in human populations.

This review examined thymic hormones and their neuroendocrine interactions in treating congenital and acquired immune deficiencies, with specific attention to TB4-Fragment. The article synthesized evidence on how thymic hormones regulate immune function through interactions with the nervous and endocrine systems, and discussed their potential clinical applications in various immunodeficiency conditions. This is a review of preclinical and clinical literature rather than original human clinical research.